NMRA|Neumora Therapeutics Inc|Price:2.120|Chg%:0.16

More Details of Neumora Therapeutics Inc Company

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Neumora Therapeutics Inc Info



Ticker SymbolNMRA

Company nameNeumora Therapeutics Inc

IPO dateSep 15, 2023

CEOBerns (Paul L)

Number of employees110

Security typeOrdinary Share

Fiscal year-endSep 15

Address260 Arsenal Place, Suite 1

CityWATERTOWN

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code02472

Phone18577600900

Websitehttps://neumoratx.com/

Ticker SymbolNMRA

IPO dateSep 15, 2023

CEOBerns (Paul L)

Company Executives of Neumora Therapeutics Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Paul L. Berns

Chairman of the Board, Chief Executive Officer, Co-Founder

7.68M

+242774.00%

Dr. Daljit Singh (Bill) Aurora, Pharm.D.

Chief Operating and Development Officer

130.51K

+41578.00%

Ms. Kristina M. Burow

Independent Director

47.72K

+20100.00%

Mr. Michael Lee Milligan

Chief Financial Officer, Principal Accounting Officer

22.47K

-1978.00%

Dr. Joshua Pinto, Ph.D.

President

--

Mr. Alaa A. Halawa

Independent Director

--

Dr. Maykin Ho, Ph.D.

Independent Director

--

-20100.00%

Mr. Matthew K. (Matt) Fust

Independent Director

--

Mr. David Piacquad

Independent Director

--

Ms. Helen Rubinstein

IR Contact Officer

--

Name

Name/Position

Position

Shareholding

Change

Mr. Paul L. Berns

Chairman of the Board, Chief Executive Officer, Co-Founder

7.68M

+242774.00%

Dr. Daljit Singh (Bill) Aurora, Pharm.D.

Chief Operating and Development Officer

130.51K

+41578.00%

Ms. Kristina M. Burow

Independent Director

47.72K

+20100.00%

Mr. Michael Lee Milligan

Chief Financial Officer, Principal Accounting Officer

22.47K

-1978.00%

Dr. Joshua Pinto, Ph.D.

President

--

Mr. Alaa A. Halawa

Independent Director

--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.

Relevant data have not been disclosed by the company yet.

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Tue, Nov 18

Shareholders

Shareholder Types

Shareholders

Proportion

Amgen Inc

21.46%

ARCH Venture Partners

20.54%

Berns (Paul L)

4.66%

SB Global Advisers Ltd

3.97%

The Vanguard Group, Inc.

2.75%

Other

46.62%

Shareholders

Proportion

Amgen Inc

21.46%

ARCH Venture Partners

20.54%

Berns (Paul L)

4.66%

SB Global Advisers Ltd

3.97%

The Vanguard Group, Inc.

2.75%

Other

46.62%

Shareholder Types

Shareholders

Proportion

Investment Advisor

21.79%

Venture Capital

21.66%

Corporation

21.46%

Individual Investor

5.33%

Hedge Fund

4.05%

Investment Advisor/Hedge Fund

2.35%

Endowment Fund

2.01%

Research Firm

0.63%

Bank and Trust

0.03%

Other

20.69%

Institutional Shareholding



Updated: Thu, Jan 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

291

86.11M

52.25%

-29.43M

2025Q3

293

86.79M

53.64%

-40.47M

2025Q2

288

142.02M

87.70%

-25.57M

2025Q1

283

144.00M

90.43%

+12.16M

2024Q4

249

161.18M

99.54%

+45.20M

2024Q3

201

148.65M

93.66%

+40.67M

2024Q2

179

142.61M

90.03%

+47.65M

2024Q1

154

133.89M

85.01%

+50.39M

2023Q4

108

122.49M

78.90%

+50.97M

2023Q3

54

110.63M

71.42%

+110.63M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Amgen Inc

35.37M

21.46%

--

Apr 10, 2025

ARCH Venture Partners

33.85M

20.54%

+1.92M

+6.00%

Oct 27, 2025

Berns (Paul L)

7.68M

4.66%

+242.77K

+3.27%

Apr 10, 2025

SB Global Advisers Ltd

6.54M

3.97%

--

Sep 30, 2025

The Vanguard Group, Inc.

4.05M

2.46%

-713.74K

-14.99%

Sep 30, 2025

MIC Capital Management UK LLP

4.46M

2.71%

+2.23M

+100.00%

Sep 30, 2025

Invus Public Equities Advisors, LLC

4.36M

2.64%

--

Sep 30, 2025

Fidelity Management & Research Company LLC

3.50M

2.12%

-934.00

-0.03%

Sep 30, 2025

Wellcome Trust

3.31M

2.01%

--

Sep 30, 2025

ICONIQ Capital, LLC

2.56M

1.55%

--

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

Invesco Nasdaq Biotechnology ETF

0.05%

ProShares Ultra Nasdaq Biotechnology

0.04%

Invesco RAFI US 1500 Small-Mid ETF

0.02%

iShares Biotechnology ETF

0.02%

Schwab U.S. Small-Cap ETF

0.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

0%

iShares US Small-Cap Equity Factor ETF

0%

Virtus LifeSci Biotech Clinical Trials ETF

0%

Fidelity MSCI Health Care Index ETF

0%

Schwab U.S. Broad Market ETF

0%

Invesco Nasdaq Biotechnology ETF

Proportion0.05%

ProShares Ultra Nasdaq Biotechnology

Proportion0.04%

Invesco RAFI US 1500 Small-Mid ETF

Proportion0.02%

iShares Biotechnology ETF

Proportion0.02%

Schwab U.S. Small-Cap ETF

Proportion0.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proportion0%

iShares US Small-Cap Equity Factor ETF

Proportion0%

Virtus LifeSci Biotech Clinical Trials ETF

Proportion0%

Fidelity MSCI Health Care Index ETF

Proportion0%

Schwab U.S. Broad Market ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data